Zydus Lifesciences Launches Affordable OPEP Device Amid Strong Q3 Results

Zydus Lifesciences (

) has introduced PEPAIR™, India's first low-cost Oscillating Positive Expiratory Pressure (OPEP) device, targeting mucus clearance in patients with COPD, asthma, and bronchiectasis. Priced at ₹990 per unit, this drug-free, handheld tool features a patented three-resistance system to generate exhalation vibrations, addressing accessibility barriers in airway clearance therapy recommended by clinical guidelines . The launch partners with AeroDel Technology Innovations Pvt. Ltd. for development and manufacturing. Over 9 million Indians live with these chronic respiratory conditions, exacerbated by pollution, urbanization, and allergens, heightening demand for affordable solutions . Zydus, with its established respiratory portfolio including bronchodilators and inhalers, positions PEPAIR™ to fill this market gap. Supporting the development, Zydus reported robust Q3 FY26 results: net profit up 2% to ₹1,042 crore, revenue surging 30.3% to ₹6,865 crore, and EBITDA rising 31% to ₹1,817 crore with a 26.5% margin all exceeding analyst estimates. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.